CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced a conference call on May 11, 2020, at 4:30 p.m. ET to discuss its financial results for Q1 2020, which ended on March 31, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced a conference call on May 11, 2020, at 4:30 p.m. ET to discuss its financial results for Q1 2020, which ended on March 31, 2020. The call will provide an update on the company's business as it focuses on developing therapies for liver and other chronic diseases.
Investors can access the call by dialing specific numbers provided or through the company's website for a live and archived audio webcast.
Positive
- Scheduled conference call to discuss Q1 financial results and business update indicates transparency to shareholders.
Negative
- None.
Details
News Market Reaction – CBAY
The recorded move for CBAY in the trading session of this news was +1.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 11, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2020 and to provide a business update.
Conference Call Details
To access the live conference call, please dial 855-327-6837 from the U.S. and Canada, or 631-891-4304 internationally, Conference ID# 10009543. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.
About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Sloane & Company
Dan Zacchei / Joe Germani, 212-486-9500
Dzacchei@sloanepr.com / JGermani@sloanepr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.